Nuwellis Stock Earnings Reports

Nuwellis reported Q1 2026 progress as the company moves from strategic reset into execution. Key operational moves included appointing a new CFO, strengthening the Board, expanding field leadership (including a new South Texas territory), and completing a ~$5M private placement. The company closed the acquisition of Rendiatech to add automated kidney function monitoring to its cardiorenal platform and appointed Dr. Stuart Goldstein to strengthen clinical strategy. Commercially, Aquadex console and circuit sales drove revenue of $2.4M, a 26% year-over-year increase; gross margin improved to 70.1% due to better pricing, product mix, and contract manufacturing. Pediatrics is a major growth area, representing roughly 50% of U.S. revenue with 47 pediatric centers onboard. Operating expenses rose to ~$6.0M (driven by increased sales headcount), net loss was ~$4.3M, cash and restricted cash were ~$2.2M, and the company plans a cash-burn reduction initiative to cut monthly burn by ~50% by Q4 while focusing resources on high-priority growth areas. Management reiterated focus on deepening utilization in high-need accounts, advancing Rendiatech integration (targeting a new bedside urine analytics product for U.S. introduction in 2027), and sustaining financial discipline.